465 related articles for article (PubMed ID: 33687450)
1. Prolonged SARS-CoV-2 Infection in a CAR T-Cell Therapy Recipient.
Abbasi J
JAMA; 2021 Mar; 325(10):924. PubMed ID: 33687450
[No Abstract] [Full Text] [Related]
2. The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose.
Luque-Paz D; Sesques P; Wallet F; Bachy E; Ader F
Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1155-1162. PubMed ID: 35838042
[TBL] [Abstract][Full Text] [Related]
3. Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis.
Cheok KPL; Kirkwood AA; Menne T; Tholouli E; Chaganti S; Mathew A; Uttenthal B; Russell J; Irvine D; Johnson R; Nicholson E; Bazin J; Townsend W; Kuhnl A; O'Reilly M; Sanderson R; Patel A; Roddie C
Leuk Lymphoma; 2022 Aug; 63(8):1980-1984. PubMed ID: 35481791
[No Abstract] [Full Text] [Related]
4. Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy.
Bošnjak B; Odak I; Ritter C; Stahl K; Graalmann T; Steinbrück L; Blasczyk R; Falk CS; Schulz TF; Wedemeyer HH; Cornberg M; Ganser A; Förster R; Koenecke C
Front Immunol; 2021; 12():721738. PubMed ID: 34456929
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)-T-cell therapy.
Kampouri E; Hill JA; Dioverti V
Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14144. PubMed ID: 37767643
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.
Casadevall A; Henderson JP; Joyner MJ; Pirofski LA
J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33621214
[No Abstract] [Full Text] [Related]
7. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
[TBL] [Abstract][Full Text] [Related]
8. Rapid recovery of taste and smell in a patient with SARS-CoV-2 following convalescent plasma therapy.
Fisher DL; Pavel A; Malnick S
QJM; 2021 Aug; 114(5):319-320. PubMed ID: 33416888
[No Abstract] [Full Text] [Related]
9. Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19.
Zahra FT; Bellusci L; Grubbs G; Golding H; Khurana S
Ann Rheum Dis; 2022 Jul; 81(7):1044-1045. PubMed ID: 35144925
[No Abstract] [Full Text] [Related]
10. Convalescent plasma for SARS-CoV-2 infection: win or learn.
Contreras-Barbeta E; Millan A; Rello J
Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34531275
[TBL] [Abstract][Full Text] [Related]
11. [Is convalescent plasma an alternative treatment for Covid-19 patients?].
Trejo-Gómor JE; Dimas-González J; Lagunas-Martínez A
Salud Publica Mex; 2020; 62(6):870-871. PubMed ID: 33620985
[No Abstract] [Full Text] [Related]
12. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.
Wu X; Wang L; Shen L; He L; Tang K
J Hematol Oncol; 2022 Jun; 15(1):81. PubMed ID: 35710431
[TBL] [Abstract][Full Text] [Related]
13. CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines
Ma MT; Badeti S; Chen CH; Kim J; Choudhary A; Honnen B; Reichman C; Calianese D; Pinter A; Jiang Q; Shi L; Zhou R; Xu H; Li Q; Gause W; Liu D
Front Immunol; 2021; 12():652223. PubMed ID: 34367128
[TBL] [Abstract][Full Text] [Related]
14. Covid-19 convalescent plasma and SARS-CoV-2 viral variants.
Joob B; Wiwanitkit V
Transfus Clin Biol; 2021 Aug; 28(3):306. PubMed ID: 34116915
[No Abstract] [Full Text] [Related]
15. In the Limelight: September 2020.
Nath KA
Mayo Clin Proc; 2020 Sep; 95(9):1813-1815. PubMed ID: 32861318
[No Abstract] [Full Text] [Related]
16. Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps.
Garraud O; Burnouf T
Transfus Clin Biol; 2021 Aug; 28(3):225-227. PubMed ID: 34362557
[No Abstract] [Full Text] [Related]
17. The need for and challenges of comparing SARS-CoV-2 antibody assays.
Jacquot C; Feys HB
Transfus Med; 2021 Jun; 31(3):147-148. PubMed ID: 34110048
[No Abstract] [Full Text] [Related]
18. Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum.
Uriu K; Kimura I; Shirakawa K; Takaori-Kondo A; Nakada TA; Kaneda A; Nakagawa S; Sato K;
N Engl J Med; 2021 Dec; 385(25):2397-2399. PubMed ID: 34731554
[No Abstract] [Full Text] [Related]
19. Researchers Tie Severe Immunosuppression to Chronic COVID-19 and Virus Variants.
Abbasi J
JAMA; 2021 May; 325(20):2033-2035. PubMed ID: 33950236
[No Abstract] [Full Text] [Related]
20. Fast-spreading COVID variant can elude immune responses.
Callaway E
Nature; 2021 Jan; 589(7843):500-501. PubMed ID: 33479534
[No Abstract] [Full Text] [Related]
[Next] [New Search]
